drugset / Trial / NCT05065983
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
NaSingle-groupOpen-labelPrevention
Summary
The objective of this study is to assess the safety and immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine \[CHIKV VLP\], aluminum hydroxide adjuvanted).
Timeline
- Start
- 2021-10-11
- Primary completion
- 2022-05-05
- Completion
- 2022-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PXVX0317 | Vaccine | 40 ug | — |